LPA2-T33 tumors were modestly responsive to both RSL3 and neratinib monotherapy, with combination treatment with RSL3 and neratinib resulting in a statistically significant decrease in tumor size compared to either therapy alone (Fig. 2g). The gene discussed is LPAR2; the disease is neoplasm.